Full-Life Technologies Announced the Progress of its Radioisotope Manufacturing Facility in Belgium
Gembloux, Belgium, and Shanghai, China – December 5, 2024 – Full-Life Technologies (“Full-Life”, the “Company”), a fully integrated global radiotherapeutics company, today announced the progress of its radioisotope manufacturing facility in Belgium. The construction of the facility started in December 2023 and obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control in March 2024. Under full capacty, it will provide Ac-225 therapies to tens of thousands of cancer patients each year once operational.
The radioisotope manufacturing facility video is available here.
About Full-Life Technologies
Full-Life Technologies (“Full-Life”) is a clinical-stage, fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.